162 related articles for article (PubMed ID: 32724063)
1. Evaluation and modeling of direct membrane-feeding assay with Plasmodium vivax to support development of transmission blocking vaccines.
Miura K; Swihart BJ; Fay MP; Kumpitak C; Kiattibutr K; Sattabongkot J; Long CA
Sci Rep; 2020 Jul; 10(1):12569. PubMed ID: 32724063
[TBL] [Abstract][Full Text] [Related]
2. Transmission-blocking activity is determined by transmission-reducing activity and number of control oocysts in Plasmodium falciparum standard membrane-feeding assay.
Miura K; Swihart BJ; Deng B; Zhou L; Pham TP; Diouf A; Burton T; Fay MP; Long CA
Vaccine; 2016 Jul; 34(35):4145-4151. PubMed ID: 27372156
[TBL] [Abstract][Full Text] [Related]
3. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.
Miura K; Keister DB; Muratova OV; Sattabongkot J; Long CA; Saul A
Malar J; 2007 Aug; 6():107. PubMed ID: 17686163
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of two Plasmodium vivax sexual stage antigens as transmission-blocking vaccine candidates.
Zhang Y; Liu F; Zhao Y; Yang F; Bai J; Jia X; Roobsoong W; Sattabongkot J; Cui L; Cao Y; Luo E; Wang M
Parasit Vectors; 2021 Aug; 14(1):407. PubMed ID: 34399829
[TBL] [Abstract][Full Text] [Related]
5. Immunity against sexual stage Plasmodium falciparum and Plasmodium vivax parasites.
de Jong RM; Tebeje SK; Meerstein-Kessel L; Tadesse FG; Jore MM; Stone W; Bousema T
Immunol Rev; 2020 Jan; 293(1):190-215. PubMed ID: 31840844
[TBL] [Abstract][Full Text] [Related]
6. The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials.
Ramjanee S; Robertson JS; Franke-Fayard B; Sinha R; Waters AP; Janse CJ; Wu Y; Blagborough AM; Saul A; Sinden RE
Vaccine; 2007 Jan; 25(5):886-94. PubMed ID: 17049690
[TBL] [Abstract][Full Text] [Related]
7. Strong concordance between percent inhibition in oocyst and sporozoite intensities in a Plasmodium falciparum standard membrane-feeding assay.
Miura K; Swihart BJ; Deng B; Zhou L; Pham TP; Diouf A; Fay MP; Long CA
Parasit Vectors; 2019 May; 12(1):206. PubMed ID: 31060594
[TBL] [Abstract][Full Text] [Related]
8. The fibrinogen-like domain of FREP1 protein is a broad-spectrum malaria transmission-blocking vaccine antigen.
Niu G; Franc A C; Zhang G; Roobsoong W; Nguitragool W; Wang X; Prachumsri J; Butler NS; Li J
J Biol Chem; 2017 Jul; 292(28):11960-11969. PubMed ID: 28533429
[TBL] [Abstract][Full Text] [Related]
9. Overview: immunology of malaria and progress in malaria vaccine development.
Tharavanij S
Southeast Asian J Trop Med Public Health; 1992 Sep; 23 Suppl 4():71-87. PubMed ID: 1364871
[No Abstract] [Full Text] [Related]
10. Differential roles of an Anopheline midgut GPI-anchored protein in mediating Plasmodium falciparum and Plasmodium vivax ookinete invasion.
Mathias DK; Jardim JG; Parish LA; Armistead JS; Trinh HV; Kumpitak C; Sattabongkot J; Dinglasan RR
Infect Genet Evol; 2014 Dec; 28():635-47. PubMed ID: 24929123
[TBL] [Abstract][Full Text] [Related]
11. The use of transgenic parasites in malaria vaccine research.
Othman AS; Marin-Mogollon C; Salman AM; Franke-Fayard BM; Janse CJ; Khan SM
Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525963
[TBL] [Abstract][Full Text] [Related]
12. Using serological measures to monitor changes in malaria transmission in Vanuatu.
Cook J; Reid H; Iavro J; Kuwahata M; Taleo G; Clements A; McCarthy J; Vallely A; Drakeley C
Malar J; 2010 Jun; 9():169. PubMed ID: 20553604
[TBL] [Abstract][Full Text] [Related]
13. Comparative assessment of An. gambiae and An. stephensi mosquitoes to determine transmission-reducing activity of antibodies against P. falciparum sexual stage antigens.
Eldering M; Bompard A; Miura K; Stone W; Morlais I; Cohuet A; van Gemert GJ; Brock PM; Rijpma SR; van de Vegte-Bolmer M; Graumans W; Siebelink-Stoter R; Da DF; Long CA; Morin MJ; Sauerwein RW; Churcher TS; Bousema T
Parasit Vectors; 2017 Oct; 10(1):489. PubMed ID: 29041962
[TBL] [Abstract][Full Text] [Related]
14. Comparative assessment of transmission-blocking vaccine candidates against Plasmodium falciparum.
Kapulu MC; Da DF; Miura K; Li Y; Blagborough AM; Churcher TS; Nikolaeva D; Williams AR; Goodman AL; Sangare I; Turner AV; Cottingham MG; Nicosia A; Straschil U; Tsuboi T; Gilbert SC; Long CA; Sinden RE; Draper SJ; Hill AV; Cohuet A; Biswas S
Sci Rep; 2015 Jun; 5():11193. PubMed ID: 26063320
[TBL] [Abstract][Full Text] [Related]
15. Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay.
Miura K; Takashima E; Deng B; Tullo G; Diouf A; Moretz SE; Nikolaeva D; Diakite M; Fairhurst RM; Fay MP; Long CA; Tsuboi T
Infect Immun; 2013 Dec; 81(12):4377-82. PubMed ID: 24042109
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of Thai zoophilic Anophelines and suspected malaria vectors to local strains of human malaria parasites.
Somboon P; Suwonkerd W; Lines JD
Southeast Asian J Trop Med Public Health; 1994 Dec; 25(4):766-70. PubMed ID: 7667729
[TBL] [Abstract][Full Text] [Related]
17. A Novel Ex Vivo Assay to Evaluate Functional Effectiveness of Plasmodium vivax Transmission-Blocking Vaccine Using Pvs25 Transgenic Plasmodium berghei.
Cao Y; Hayashi CTH; Kumar N
J Infect Dis; 2024 Jun; 229(6):1894-1903. PubMed ID: 38408353
[TBL] [Abstract][Full Text] [Related]
18. Plasmodium vivax gametocyte proteins, Pvs48/45 and Pvs47, induce transmission-reducing antibodies by DNA immunization.
Tachibana M; Suwanabun N; Kaneko O; Iriko H; Otsuki H; Sattabongkot J; Kaneko A; Herrera S; Torii M; Tsuboi T
Vaccine; 2015 Apr; 33(16):1901-8. PubMed ID: 25765968
[TBL] [Abstract][Full Text] [Related]
19. Malaria Vaccines: Recent Advances and New Horizons.
Draper SJ; Sack BK; King CR; Nielsen CM; Rayner JC; Higgins MK; Long CA; Seder RA
Cell Host Microbe; 2018 Jul; 24(1):43-56. PubMed ID: 30001524
[TBL] [Abstract][Full Text] [Related]
20. Transmission blocking malaria vaccines: Assays and candidates in clinical development.
Sauerwein RW; Bousema T
Vaccine; 2015 Dec; 33(52):7476-82. PubMed ID: 26409813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
